Buy Live Nation (LYV) Immediately
Wall Street legend who helped create America’s stock-rating system says this stock could soon be rated a “Strong Buy” at every bank in New York City and Boston. “It’s all part of the biggest prediction of my 50-year career on Wall Street,” he says. “A massive and surprising new transition that could determine the next group of millionaires.”
Click here to learn more.
Martin A. Lehr, insider at Context Therapeutics
Martin A. Lehr Insider Alerts

Get notified the next time Martin A. Lehr buys or sells Context Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Martin A. Lehr Insider Information

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis.  In addition to his role at Context, Martin is a Director of BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

+ LinkedIn

How do I contact Martin A. Lehr?

The corporate mailing address for Mr. Lehr and other Context Therapeutics executives is 3675 Market Street, Philadelphia, Pennsylvania 19104.

Has Martin A. Lehr been buying or selling shares of Context Therapeutics?

Martin A. Lehr has not been actively trading shares of Context Therapeutics in the last ninety days. Most recently, on Thursday, December 16th, Martin A. Lehr bought 13,000 shares of Context Therapeutics stock. The stock was acquired at an average cost of $3.22 per share, with a total value of $41,860.00.

Who are Context Therapeutics' active insiders?

Context Therapeutics' insider roster includes Martin Lehr (CEO), and Alex Levit (Insider).

Are insiders buying or selling shares of Context Therapeutics?

During the last twelve months, Context Therapeutics insiders bought shares 3 times. They purchased a total of 26,000 shares worth more than $106,860.00. The most recent insider tranaction occured on December, 16th when CEO Martin A Lehr bought 13,000 shares worth more than $41,860.00.

Information on this page was last updated on 12/16/2021.

Martin A. Lehr Insider Trading History at Context Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2021Buy13,000$3.22$41,860.00View SEC Filing Icon  
10/22/2021Buy10,000$5.00$50,000.00View SEC Filing Icon  
See Full Table

Martin A. Lehr Buying and Selling Activity at Context Therapeutics

This chart shows Martin A Lehr's buying and selling at Context Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Context Therapeutics Company Overview

Context Therapeutics logo
Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $2.07
Low: $2.06
High: $2.18

50 Day Range

MA: $3.95
Low: $2.07
High: $7.16

2 Week Range

Now: $2.07
Low: $2.06
High: $10.87

Volume

388,759 shs

Average Volume

930,704 shs

Market Capitalization

$22.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Buy Live Nation (LYV) Immediately
Wall Street legend who helped create America’s stock-rating system says this stock could soon be rated a “Strong Buy” at every bank in New York City and Boston. “It’s all part of the biggest prediction of my 50-year career on Wall Street,” he says. “A massive and surprising new transition that could determine the next group of millionaires.”
Click here to learn more.